DSIP 5mg

Delta Sleep Inducing Peptide (DSIP) regulates endocrine and physiological processes to improve sleep quality, reduce oxidative stress, and normalize heart function. It is being studied foDelta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide composed of nine amino acids. It was first isolated in 1977 from the brains of rats during slow-wave sleep. DSIP is primarily known for its potential to promote deep, restorative sleep. 

Despite its name, the connection between DSIP and sleep has been difficult to pin down. In some studies, DSIP promoted slow-wave sleep and suppressed paradoxical sleep, while other studies have found no impact on sleep at all. Overall, DSIP appears to help normalize sleep and regulate dysfunction in sleep cycles.

Mechanism of Action

DSIP is believed to exert its effects through several mechanisms:

• GABAergic System: DSIP may act as a GABA potentiator, enhancing the inhibitory effects of GABA, a neurotransmitter that promotes relaxation and sleep.
• NMDA Receptor Modulation: It has been suggested that DSIP acts as a negative allosteric modulator of NMDA receptors, which are involved in synaptic plasticity and memory function.
• Endocrine Regulation: DSIP has been shown to influence the release of various hormones, including corticotropin, luteinizing hormone, and somatotropin, indicating a role in neuroendocrine regulation.

DSIP Research

The Relationship of DSIP to Sleep

Despite its name, DSIP’s exact role in sleep regulation remains unclear. Early studies in rabbits yielded mixed results—some found DSIP promoted slow-wave sleep and suppressed REM sleep, others found no sleep effects, and one showed initial arousal followed by sedation. Overall, DSIP appears to normalize and regulate sleep cycles, particularly improving sleep structure and reducing sleep latency in chronic insomnia. Subjectively, DSIP increases feelings of sleepiness and sleep time (by 59% vs placebo) and shortens sleep onset, though EEG data don’t show typical sedation, likely due to limitations in measuring natural sedation.

DSIP and Chronic Pain

Chronic pain management is challenging due to side effects of NSAIDs and opioids. A small human preclinical trial found DSIP reduces pain perception, improves mood, and mitigates withdrawal symptoms during cessation of long-term analgesics. In rats, DSIP acts on central opioid receptors to produce dose-dependent analgesia without the dependency risks of opioids.

DSIP and Metabolism

DSIP helps maintain efficient mitochondrial oxidative phosphorylation during hypoxia, preventing a switch to less efficient oxygen-independent metabolism that produces toxic byproducts. This suggests DSIP may be protective in stroke or heart attack by preserving mitochondrial function and reducing free radical production, implying possible antioxidant and anti-aging benefits.

DSIP and Depression

DSIP regulates monoamine oxidase A (MAO-A) and serotonin levels, implicating it in depression. Depressed patients show reduced DSIP levels in cerebrospinal fluid. DSIP is linked to the hypothalamic-pituitary-adrenal axis and may influence suicidal behavior, but has not yet been tested as a depression treatment.

DSIP in Withdrawal and Addiction

Clinical trials with 107 patients undergoing alcohol or opiate withdrawal showed DSIP improved or resolved withdrawal symptoms in 87-97% of cases. Opiate withdrawal required more injections and longer treatment. These results suggest DSIP as a promising adjunct in detoxification therapies.

DSIP and Cancer Prevention

In mice given monthly DSIP injections starting at 3 months old until death, tumor development was reduced 2.6-fold and chromosomal defects decreased by 22.6%. This highlights DSIP’s potential as a cancer prevention agent, reducing tumor incidence and genetic damage.

DSIP as Cancer Adjuvant

Chemotherapy often causes CNS side effects including motor and cognitive impairments, especially in children. DSIP and its analogue Deltaran improve CNS blood supply and protect against ischemic and chemotherapy-induced damage. In animal models, Deltaran improved survival rates significantly following cerebral ischemia.

Other Physiological and Muscle-Building Effects

Though discovered in the brain during slow-wave sleep, DSIP is present in high levels in peripheral tissues, suggesting broader physiological roles beyond sleep. DSIP inhibits somatostatin, promoting muscle hypertrophy and hyperplasia. It also regulates blood pressure, heart rate, thermogenesis, and lymphokine systems, sometimes before sleep onset, indicating preparation of the body for sleep.

Pharmacology and Usage

DSIP exhibits minimal side effects with low oral and excellent subcutaneous bioavailability in mice. Mouse dosages do not scale directly to humans. DSIP sold by Peptide Sciences is for educational and research purposes only, not for human use. Purchase only if licensed.

Research Applications

DSIP is primarily utilized in scientific studies focusing on:

• Sleep Regulation: Investigating its potential to modulate sleep architecture and improve sleep quality.
• Stress Response: Exploring its role in regulating the hypothalamic-pituitary-adrenal (HPA) axis and mitigating stress-induced hormonal fluctuations.
• Pain Management: Assessing its effects on pain perception and potential analgesic properties.
• Neuroprotection: Studying its potential to protect neurons from damage and support recovery from neurological injuries.
• Endocrine Function: Examining its impact on hormone secretion and overall endocrine system balance.

Product Specifications

• Form: Lyophilized (freeze-dried) powder for reconstitution.
• Purity: Typically ≥98%, ensuring high-quality material for research purposes.
• Packaging: Each vial contains 5 mg of DSIP.
• Storage: Store lyophilized DSIP at temperatures below -18°C. After reconstitution, store at 4°C and use within 2-7 days.r potential depression treatment and overall nervous system support. Restore restful sleep and reduce stress with DSIP. Purchase today for better nights and improved wellbeing!

Referenced Citations

1. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep
2. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
3. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
4. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
5. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes
6. Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP)
7. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia
8. Effects of delta-sleep inducing peptide (DSIP) and analogues on monoamine oxidase type A in rat brain under hypoxia
9. Decreased concentrations of delta-sleep inducing peptide in plasma and cerebrospinal fluid from depressed patients
10. Delta sleep-inducing peptide (DSIP): overview and possible relationship to psychiatric illnesses
11. High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder
12. Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial
13. DSIP in the treatment of withdrawal syndromes from alcohol and opiates
14. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female mice
15. Sinyukhin, A.B., et al., “Delta sleep-inducing peptide analogue corrects CNS functional state of children treated with antiblastomic therapy,” Eur. Neuropsychopharmacol., vol. 19, 2009.
16. Koplik, E.V., et al., “Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection,” Neurosci. Behav. Physiol., vol. 38, no. 9, 2008.
17. DSIP: the sleep peptide or an unknown hypothalamic hormone?
18. Yehuda, S. & Carasso, R.L., “The Effects of DSIP on Pain Threshold During Light and Dark Periods in Rats are not Naloxone-Sensitive,” International Journal of Neuroscience, 1967. 
19. Graf, M., Christen, H., & Schoenenberger, G., “DSIP, DSIPP and circadian motor activity of rats under continuous light,” Peptides, 1982. 
20. Yehuda, S. & Carasso, R.L., “DSIP—a tool for investigating the sleep onset mechanism: a review,” International Journal of Neuroscience, 1988. 
21. Yehuda, S., Kastin, A.J., & Coy, D.H., “Thermoregulatory and locomotor effects of DSIP: Paradoxical interaction with d-amphetamine,” Pharmacology Biochemistry and Behavior, 1980.